KMT2A and acute lymphoblastic leukemia: Within the MLL-10 trial, enrolling 90 infants between 2011 and 2015 in Japan, 3-year EFS and 3-year OS rates for the 75 patients with KMT2A-rearranged ALL were 66.2% [standard error (SE), 5.6%], and 83.9% (SE, 4.3%), respectively, overall.